{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:10:02Z","timestamp":1792692602917,"version":"4.5.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"4","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,27]]},"DOI":"10.1182\/bloodadvances.2023012336","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T16:09:08Z","timestamp":1704902948000},"page":"895-898","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Answering the \u201cDoctor, can CAR-T therapy cause cancer?\u201d question in clinic"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Poh","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-3882","authenticated-orcid":false,"given":"Alexandre V.","family":"Hirayama","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8409","authenticated-orcid":false,"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1446","authenticated-orcid":false,"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-4947","authenticated-orcid":false,"given":"Hans-Peter","family":"Kiem","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6834","authenticated-orcid":false,"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2024022615173904600_bib1","author":"Food and Drug Administration","year":"28\u00a0 2023"},{"key":"2024022615173904600_bib2","article-title":"FDA opens review of CAR-T safety after identifying 19 cases of post-treatment blood cancer","author":"DeFeudis","year":"28  2023","journal-title":"Endpoints News"},{"key":"2024022615173904600_bib3","article-title":"FDA investigates \u2018serious risk\u2019 of secondary cancer following CAR-T treatment","author":"Liu","year":"28  2023","journal-title":"Fierce Pharma"},{"issue":"suppl 1","key":"2024022615173904600_bib4","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"key":"2024022615173904600_bib5","unstructured":"Kolata\n              G\n            \n          . Innovative cancer treatment may sometimes cause cancer, FDA says. New York Times. 28 November 2023. Accessed 23 January 2024. https:\/\/www.nytimes.com\/2023\/11\/28\/health\/fda-car-t-blood-cancer.html."},{"issue":"14","key":"2024022615173904600_bib6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2024022615173904600_bib7","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024022615173904600_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024022615173904600_bib9","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024022615173904600_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2024022615173904600_bib11","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"suppl 16","key":"2024022615173904600_bib12","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2023.41.16_suppl.8032","article-title":"Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed\/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT)","volume":"41","author":"Delforge","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"2024022615173904600_bib13","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma","volume":"128","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2024022615173904600_bib14","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024022615173904600_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.2020010497","article-title":"The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma","volume":"138","author":"Chihara","year":"2021","journal-title":"Blood"},{"key":"2024022615173904600_bib16","unstructured":"CARVYKTI (ciltacabtagene autoleucel)\n          . Package insert. Janssen Biotech, Inc. 2023. https:\/\/www.fda.gov\/media\/156560\/download."},{"issue":"10297","key":"2024022615173904600_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"2024022615173904600_bib18","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2024022615173904600_bib19","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1097\/HS9.0000000000000957","article-title":"Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients","volume":"7","author":"Panagiota","year":"2023","journal-title":"Hemasphere"},{"issue":"6","key":"2024022615173904600_bib20","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","article-title":"Prevalence and variation of\u00a0CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment","volume":"6","author":"Teipel","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024022615173904600_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2022-165646","article-title":"Comprehensive characterization of prolonged unexplained cytopenias in relapsed\/refractory multiple myeloma patients following BCMA-directed CAR-T cell therapy","volume":"140","author":"Thibaud","year":"2022","journal-title":"Blood"},{"key":"2024022615173904600_bib22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.06.015","article-title":"Characteristics and outcomes of patients with multiple myeloma who developed therapy-related acute myeloid leukemia and myelodysplastic syndrome after autologous cell transplantation","author":"Yalniz","year":"10  2023","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2024022615173904600_bib23","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1182\/blood-2022-170859","article-title":"Survival of patients with multiple myeloma diagnosed with second primary malignancies: an ASCO Cancerlinq analysis","volume":"140","author":"Cooper","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024022615173904600_bib24","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"2024022615173904600_bib25","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2024022615173904600_bib26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","article-title":"Absence of replication-competent Lentivirus in the clinic: analysis of infused T cell products","volume":"26","author":"Cornetta","year":"2018","journal-title":"Mol Ther"},{"issue":"3","key":"2024022615173904600_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","article-title":"Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study","volume":"93","author":"Sacchi","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"2024022615173904600_bib28","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"7709","key":"2024022615173904600_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"15","key":"2024022615173904600_bib30","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv"},{"issue":"16","key":"2024022615173904600_bib31","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell\u00a0lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2024022615173904600_bib32","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2024022615173904600_bib33","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.3324\/haematol.2016.146118","article-title":"Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma","volume":"101","author":"Blombery","year":"2016","journal-title":"Haematologica"},{"issue":"23","key":"2024022615173904600_bib34","doi-asserted-by":"crossref","first-page":"34201","DOI":"10.18632\/oncotarget.9077","article-title":"Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma","volume":"7","author":"Ehrentraut","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"2024022615173904600_bib35","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of second primary\u00a0malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv"},{"issue":"25","key":"2024022615173904600_bib36","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2217\/fon-2022-0421","article-title":"Patient preferences for treatment in relapsed\/refractory diffuse large B-cell lymphoma: a discrete choice experiment","volume":"18","author":"Birch","year":"2022","journal-title":"Future Oncol"},{"issue":"22","key":"2024022615173904600_bib37","first-page":"2698","article-title":"Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering","volume":"141","author":"Odak","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024022615173904600_bib38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/leu.2016.180","article-title":"Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors","volume":"31","author":"Monjezi","year":"2017","journal-title":"Leukemia"},{"key":"2024022615173904600_bib39","author":"Food and Drug Administration","year":"\u00a02020"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/895\/2215181\/blooda_adv-2023-012336-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/895\/2215181\/blooda_adv-2023-012336-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T15:17:56Z","timestamp":1708960676000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/4\/895\/507109\/Answering-the-Doctor-can-CAR-T-therapy-cause"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012336","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}